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Multivalency eﬀects on Pseudomonas aeruginosa
bioﬁlm inhibition and dispersal by glycopeptide
dendrimers targeting lectin LecA†
Myriam Bergmann,a Gaëlle Michaud,a Ricardo Visini,a Xian Jin,a Emilie Gillon,b
Achim Stocker,a Anne Imberty,b Tamis Darbre*a and Jean-Louis Reymond*a
The galactose speciﬁc lectin LecA partly mediates the formation of antibiotic resistant bioﬁlms by Pseudo-
monas aeruginosa, an opportunistic pathogen causing lethal airways infections in immunocompromised
and cystic ﬁbrosis patients, suggesting that preventing LecA binding to natural saccharides might provide
new opportunities for treatment. Here 8-fold (G3) and 16-fold (G4) galactosylated analogs of GalAG2, a
tetravalent G2 glycopeptide dendrimer LecA ligand and P. aeruginosa bioﬁlm inhibitor, were obtained by
convergent chloroacetyl thioether (ClAc) ligation between 4-fold or 8-fold chloroacetylated dendrimer
cores and digalactosylated dendritic arms. Hemagglutination inhibition, isothermal titration calorimetry
and bioﬁlm inhibition assays showed that G3 dendrimers bind LecA slightly better than their parent G2
dendrimers and induce complete bioﬁlm inhibition and dispersal of P. aeruginosa bioﬁlms, while G4 den-
drimers show reduced binding and no bioﬁlm inhibition. A binding model accounting for the observed
saturation of glycopeptide dendrimer galactosyl groups and LecA binding sites is proposed based on the
crystal structure of a G3 dendrimer LecA complex.
Introduction
Pseudomonas aeruginosa is an opportunistic Gram negative
human pathogen causing lethal airways infections in immuno-
compromised and cystic fibrosis patients by forming antibiotic
resistant biofilms.1 One of the therapeutic approaches to fight
these infections consists of developing biofilm inhibitors to
restore antibiotic sensitivity with a reduced eﬀect of the resist-
ance phenomena.2 It has been shown that tissue attachment
and biofilm formation in P. aeruginosa are mediated in part by
the galactose specific lectin LecA (PA-IL)3 and the fucose
specific lectin LecB (PA-IIL),4 as evidenced by the impaired
biofilm formation in deletion mutants5 and case reports of
treating P. aeruginosa infections using lectin-binding sacchar-
ide solutions,6 leading to the hypothesis that targeted inhibi-
tors of these lectins might allow control of biofilms.7
Following this hypothesis ligands of LecA,8 LecB,8 or both9
have been reported featuring various monovalent or multi-
valent glycosides displayed on a multivalent scaﬀold.10
However only very few examples have been reported to actually
interfere with Pseudomonas aeruginosa biofilm formation.11 In
particular we recently reported glycopeptide dendrimers dis-
playing four α-L-C-fucoside groups (FD2: (Fuc-α-CH2CO-Lys-
Pro-Leu)4(Lys-Phe-Lys-Ile)2Lys-His-Ile-NH2)
12 or analogs with
four galactoside groups (GalAG2: (Gal-β-OC6H4CO-Lys-Pro-
Leu)4(Lys-Phe-Lys-Ile)2Lys-His-Ile-NH2; GalBG2: (Gal-β-S
CH2CH2CO-Lys-Pro-Leu)4(Lys-Phe-Lys-Ile)2Lys-His-Ile-NH2)
13 at
the end of a common second generation (G2) peptide dendri-
mer scaﬀold.14 These dendrimers bound tightly to their
respective lectin, and inhibited the formation and induced
partial dispersion of P. aeruginosa biofilms, representing an
interesting example of bioactive synthetic dendrimers.15
Tight lectin binding and biofilm inhibition by these tetra-
valent G2 dendrimers depended on a multivalency eﬀect since
the lower generation analogs (G0 and G1) were essentially in-
active.16 In the case of the GalAG2 lectin binding was
enhanced by a specific CH–π interaction between the (ε)-CH of
His50 on LecA and the aromatic ring of the GalA aglycone
leading to further binding interactions between the terminal
tripeptide arm of the dendrimer and LecA, however optimiz-
ation of the amino acid sequence of this tripeptide only
resulted in modest activity improvements.17 Considering that
many of the reported high aﬃnity multivalent glycosidic
ligands for lectins feature an 8-fold or higher multivalency, we
asked the question whether the binding aﬃnity and biological
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activity of dendrimers GalAG2 and GalBG2 might be increased
in higher valency analogs as observed in other series of tight
binding LecA ligands.8 Various G3 and G4 analogs of GalAG2
and GalBG2 were prepared using the multiple chloroacetyl
cysteine (ClAc) thioether ligation as the key step.18 Hemaggluti-
nation inhibition, isothermal titration calorimetry and biofilm
inhibition assays are reported that show that G3 dendrimers
bind LecA slightly better than their parent G2 dendrimers and
induce complete biofilm inhibition and dispersal of P. aerugi-
nosa biofilms, while G4 dendrimers have reduced binding and
no biofilm inhibition. A binding model accounting for the
observed saturation of glycopeptide dendrimer galactosyl
groups and LecA binding sites is proposed based on a crystal
structure of a G3 dendrimer LecA complex.
Results and discussion
Synthesis
Although we previously reported a single case of a
G3 glycopeptide dendrimer by direct SPPS,12c the synthesis
was diﬃcult and the isolated yield was very low due to in-
complete coupling of the glycosidic end group to the multiple
N-termini even with low loading resin (∼0.2 mmol g−1) and
large excess of glycosylated reagent. This is probably a result of
the steric crowding in the G3 dendrimer with some of the
amino termini not exposed to the coupling reagents. This step
proved to be a limiting factor across various peptide dendri-
mers and carbohydrate building blocks even for G2 peptide
dendrimers despite the fact that the reaction is a standard
amide bond formation step. We therefore turned our attention
to a convergent approach using our recently reported multi-
valent ClAc ligation method as an eﬃcient strategy to access
G3 and G4 peptide dendrimers (Fig. 1).18
SPPS was first used to prepare a G1 glycopeptide dendrimer
featuring the N-terminal dipeptide LysPro of GalAG2 known to
engage in direct contact with the lectin, which was acylated at
its two N-termini with either 4-carboxyphenyl-β-galactoside to
yield GalAG1-Cys or carboxypropyl-β-thiogalactoside to yield
GalBG1-Cys. The carbohydrate building block coupling step
was not problematic at the G1 level and both products were
obtained in good yield after purification by preparative HPLC.
The amino acid sequence of GalAG2 was then used to design
the 2-fold, 4-fold and 8-fold chloroacetylated core dendrimers
ClAcG1, ClAcG2 and ClAcG3 consisting of dipeptide branches.
The chloroacetylated dendrimer cores ClAcPSG2 and ClAcPSG3
were also prepared since they were found previously to give
high yields in ClAc ligation reactions.18 The isolated yields of
these various chloroacetylated core dendrimers after SPPS and
HPLC purification were above 25% for G1 and G2, but only
3–5% for G3 cores, reflecting the generally more diﬃcult syn-
thesis of G3 peptide dendrimers (Table 1).
The ClAc ligation was then performed to append to
diﬀerent dendrimer cores multiple copies of the GalAG1-Cys
dendrimer bearing a phenyl-β-galactoside LecA ligand. Dendri-
mers ClAcG1 and ClAcG2 were also ligated to GalBG1-Cys to
obtain G2 and G3 analogs with a thiopropyl-β-galactoside end-
group. The ligation reactions generally proceeded cleanly and
gave isolated yields in the range 64–80%, except for GalAxG4
which was obtained in only 12% yield due to a diﬃcult purifi-
cation process.
Hemagglutination inhibition assays
Binding of the various glycopeptide dendrimers to lectin LecA
was first investigated in a hemagglutination inhibition assay
(Table 2, left part). In this assay compounds are tested in two-
fold dilution series for their inhibition of the agglutination of
erythrocytes induced by the lectin, providing minimal hemag-
glutination inhibition concentration (MIC) values. The MIC
values are then scaled to the reference MIC value of free galac-
tose in each assay to yield relative potencies (r.p.) of inhibition.
Although absolute MIC values of both test compounds and the
reference galactose may vary depending on the erythrocyte
source and lectin concentration, r.p. values are quite reprodu-
cible and a good indicator of multivalent binding potential.
Here the primary r.p. values were further converted to a
secondary r.p. value by scaling to the r.p. of the parent mono-
valent glycopeptides GalAG0 and GalBG0 as references. This
allowed the quantification of multivalency eﬀects indepen-
dently of aﬃnity eﬀects on monovalent ligand binding. These
eﬀects were quite substantial in the case of GalAG0, which
inhibits hemagglutination at a 40-fold lower concentration
than free D-galactose. A similar eﬀect also occurs with p-nitro-
phenyl-β-galactoside and reflects a productive CH–π interaction
of the aromatic aglycone with the C(ε)–H of His50 on the
lectin.17 The r.p. values were furthermore scaled to the number
of galactosyl endgroup (nGal) to correct for multivalency.
In the phenyl-galactoside (GalA) series there was no signifi-
cant increase in r.p./nGal in the divalent dendrimer GalAG1,
but the tetravalent dendrimer GalAG2 was 26-fold stronger
than GalAG0 on a per galactose basis. A comparable multi-
valency eﬀect was obtained with the tetravalent ClAc analog
GalAxG2 (r.p./nGal = 31), showing that the modification of the
peptide dendrimer backbone performed to enable the conver-
gent ClAc ligation did not influence hemagglutination inhi-
bition significantly. Increasing the dendrimer size to octavalency
resulted in a more modest, 4-fold increase in relative potency per
galactosyl endgroup with GalAxG3 (r.p./nGal = 125), respectively a
14-fold increase in its analog GalAxPSG3 (r.p./nGal = 375).
However there was no further increase in relative potency at the
G4 level, with the 16-valent GalAxG4 (r.p./nGal = 50) showing a
2.5-fold drop and GalAxPSG4 (r.p./nGal = 475) a 1.3-fold increase
in potency relative to the corresponding G3 dendrimers. In the
thiopropyl-galactoside (GalB) series multivalency eﬀects in
hemagglutination inhibition were much weaker, with r.p./nGal
values increasing only up to 8-fold in GalBxG3.
Isothermal titration calorimetry (ITC)
Multivalency eﬀects in the dendrimer LecA interactions were
also investigated by ITC using p-nitrophenyl-β-galactoside
(KD = 16 µM) as a reference. Binding enthalpies ΔH and dis-
sociation constants KD were determined experimentally by
Paper Organic & Biomolecular Chemistry
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titrating the various ligands into a LecA solution, and used to
calculate binding entropies ΔS and binding free energies ΔG
(Table 2, right part, and ESI Fig. S47†). The binding enthalpy
ΔH amounted to approximately 14 kcal mol−1 per galactosyl
end group across all the ligands tested. The GalA ligands
showed generally stronger binding compared to the corres-
ponding GalB ligands, implying a smaller entropic penalty on
binding consistent with their more rigid structures and the
burial of a larger hydrophobic surface area upon lectin
binding. The percentage of bound galactose per dendrimer
was also obtained, a value which was somewhat imprecise due
to small errors in concentration determination caused by
varying amounts of water in the lyophilized powders of the
purified dendrimers. Values >80% were interpreted as com-
plete engagement of all dendrimer galactosyl groups with the
lectin, with incomplete binding observed only in the case of
the G4 dendrimer GalAPSG4 (40% bound galactose).
In each series the multivalency eﬀect on binding was quan-
tified by the relative potency of binding per galactosyl end-
group (r.p./nGal), which was calculated from the ratio between
the KD of the reference monovalent glycotripeptide ligand
GalAG0 or GalBG0 and the KD of the multivalent dendrimer.
In the GalA series the relative potency increase in the G0/G1/
G2 series (1/18/296) was much stronger than that observed in
the hemagglutination assay (1/1.3/26). A further 1.4-fold
increase in relative potency occurred in the homologous ClAc
Fig. 1 Convergent synthesis and structural formula of the octavalent G3 glycopeptide dendrimer GalAxG3 with the corresponding sequence nota-
tion. Sequences are written with N-terminus at left and C-terminus at right, the C-terminus of the peptide is carboxamide (CONH2). One letter
codes are used for standard amino acids, the branching diamino acid lysine is in italics and extended on both amino groups, x = –S–CH2–CO–. The
detailed structure of the terminal galactosides abbreviated GalA and GalB in the abbreviated sequence notation of the dendrimers used in Table 1
and 2 are shown at top right. Conditions: (a) SPPS: Fmoc deprotection with piperidine/DMF 1 : 4 (v/v), 2 × 15 min; amino acid coupling (3 eq. Fmoc-
aa-OH, 3 eq. PyBOP, 5 eq. DIEA in NMP), 2–4 hours; carbohydrate coupling: 4 eq. Ac4GalA-OH, 3 eq. HCTU, 5 eq. DIPEA in NMP, overnight; (b) de-
acetylation: MeOH/25% NH3/H2O (8 : 1 : 1, v/v/v); (c) cleavage: TFA/TIS/H2O (95 : 2.5 : 2.5, v/v/v); (d) RP-HPLC puriﬁcation; (e) ClAc ligation: ClAcG2
(1 eq.), GalAG1-Cys (6 eq.), KI (20 eq.) DIPEA (55 eq.) in DMF/H2O (1 : 1, v/v), RT, overnight under an argon atmosphere.
Organic & Biomolecular Chemistry Paper
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Table 1 Convergent synthesis of glycopeptide dendrimers using the multivalent ClAc ligation
Name Sequencea MS calc./obs.b Yield mgc (%)
Components from SPPS
GalAG1-Cys (GalA-KP)2KIC 1376.6/1377 63 (41.6%)
GalBG1-Cys (GalB-KP)2KIC 1312.6/1312.6 57 (39.5%)
ClAcG1 (ClAc-KI)2KHI 1031.1/1030 41.4 (36.55%)
ClAcG2 (ClAc-KP)4(KKI)2KHI 2341.6/2341 64 (25%)
ClAcG3 (ClAc-KP)8(KLF)4(KKI)2KHI 5102.7/5102 19.3 (3.4%)
ClAcPSG2 (ClAc-PS)4(KPS)2KPS 1996.8/1996.9 66 (30%)
ClAcPSG3 (ClAc-PS)8(KPS)4(KPS)2KPS 4289/4290 25 (5%)
GalAPSG2 (GalA-KPL)4(KPS)2KPS 3437.9/3478 26.4 (6%)
Dendrimers prepared by ClAc ligation
GalAxG2 (GalA-KP)4(KICxKI)2KHI 3711.3/3711 6.9 (64%)
GalAxG3 (GalA-KP)8(KICxKP)4(KKI)2KHI 7702/7701 7.3 (70%)
GalAxG4 (GalA-KP)16(KICxKP)8(KLF)4(KKI)2KHI 15823.6/15 825 1.1 (12%)
GalAxPSG3 (GalA-KP)8(KICxPS)4(KPS)2KPS 7357.3/7358 9.7 (74.5%)
GalAxPSG4 (GalA-KP)16(KICxPS)8(KPS)4(KPS)2KPS 15009.9/15010.6 9.1 (80.8%)
GalBxG2 (GalB-KP)4(KICxKI)2KHI 3583.4/3582.7 6.7 (64.5%)
GalBxG3 (GalB-KP)8(KICxKP)4(KKI)2KHI 7446.2/7445 6.2 (64%)
a Sequence notation for peptide dendrimers using single letter amino acid codes for L-amino acids and indicating the branching lysine in italics.
See Fig. 1 for the correspondence between sequence notation and complete structural formula, illustrated for dendrimer GalAxG3. Further
abbreviations: ClAc = ClCH2CO–, x = –CH2SCH2CO–, GalA = 4-(β-galactosyloxy)benzoyl, GalB = (β-galactosyl)SCH2CH2CO, the peptide C-terminus
is carboxamide (CONH2).
b ESI+ or MALDI. c Yields are for purified compounds after SPPS (upper part) or ClAc ligation (lower part) and
preparative HPLC.
Table 2 Hemagglutination assay and isothermal titration calorimetry data for P. aeruginosa LecA binding
Ligand Sequencea
Hemagglutination
assayb Isothermal titration calorimetry (ITC)c
nGal MIC µM r.p./n N
% bnd
Gal
ΔH
[kcal mol−1] −TΔS ΔG
KD
[nM]
r.p./
nGal
D-Galactose 1 42 000
(3125*)
— — — — — — — —
NPG p-Nitrophenyl-β-galactoside 1 — — 0.91 ± 0.03 — −10.6 ± 0.5 4.04 6.53 16 000 ± 500 —
IPTG Isopropyl-β-thiogalactoside 1 10 400 — — — — — — — —
GalAG0 (GalA-KPL) 1 80* 1 0.65 ± 0.02 100 −17.8 ± 0.3 10.2 −7.5 2960 ± 50 1
GalAG1 (GalA-KPL)2KHI 2 31* 1.3 0.302 ± 0.003 93 −29 ± 0.5 19.3 −9.7 83 ± 12 18
GalAG2 (GalA-KPL)4(KFKI)2KHI 4 0.78* 26 0.136 ± 0.001 84 −69 ± 1.1 57 −11.7 2.5 ± 0.1 296
GalAxG2 (GalA-KP)4(KICxKI)2KHI 4 8.3 31 0.16 ± 0.009 98 −54 ± 1 43 −11.1 6.9 ± 1.4 107
GalAxG3 (GalA-KP)8(KICxKP)4(KKI)2KHI 8 1.04 125 0.064 ± 0.01 79 −115 ± 8 103.0 −11.7 2.5 ± 0.2 148
GalAxG4 (GalAKP)16(KICxKP)8(KLF)4(KKI)2KHI 16 1.28 50 — — — — — — —
GAlAPSG2 (GalA-KPL)4(KPS)2KPS 4 0.78 40 — — — — — — —
GalAxPSG3 (GalA-KP)8(KICxPS)4(KPS)2KPS 8 0.35 375 0.096 ± 0.001 >100 −92 ± 0.5 81 −11.4 4.2 ± 0.2 88
GalAxPSG4 (GalAKP)16(KICxPS)8(KPS)4(KPS)2KPS 16 0.14 475 0.033 ± 0.001 41 −217 ± 17 206 −11.5 3.4 ± 0.4 54
GalBG0 (GalB-KPL) 1 2500* 1 0.71 ± 0.01 100 −14 ± 0.04 7.8 −6.0 37 000 ± 800 1
GalBG1 (GalB-KPL)2KHI 2 630* 1.9 0.37 ± 0.02 >100 −20 ± 0.1 12 −8.2 1060 ± 160 18
GalBG2 (GalB-KPL)4(KFKI)2KHI 4 125* 4.8 0.18 ± 0.02 >100 −43 ± 1 33 −10.1 40 ± 1 230
GalBxG2 (GalB-KP)4(KICxKI)2KHI 4 125* 4.8 0.14 ± 0.001 79 −47 ± 6 37 −11.2 33 ± 25 280
GalBxG3 (GalB-KP)8(KICxKP)4(KKI)2KHI 8 37.5* 8.3 0.08 ± 0.01 90 −90 ± 9 79 −11.4 5.9 ± 2 785
a Sequence notation for peptide dendrimers using single letter amino acid codes for L-amino acids and indicating the branching lysine in italics.
See Fig. 1 for the correspondence between sequence notation and complete structural formula, illustrated for dendrimer GalAxG3. Further
abbreviations: GalA = 4-(β-galactosyloxy)benzoyl, GAlB = (β-galactosyl)SCH2CH2CO, x = –CH2SCH2CO–, the peptide C-terminus is carboxamide
(CONH2).
bMinimal hemagglutination inhibition concentrations (MIC) were determined in two diﬀerent series with the MIC for galactose being
42 mM or 3.125 mM, marked with *, nGal is the number of galactosyl groups per compound, r.p./n is the relative potency per galactosyl group
relative to free galactose as a reference: MIC(galactose)/(n × MIC(compound)), r.p./nGalA or B is the relative potency per galactosyl group relative
to GalAG0 or GalBG0 as a reference: MIC(GalAG0 or GalBG0)/(n × MIC(compound)). c Thermodynamic parameters and dissociation constants KD
are reported as an average of two independent runs from ITC in 20 mM Tris, 100 mM NaCl, 100 µM CaCl2, pH = 7.5. Titration concentrations
(ligand/LecA) are the following: NPG (3 mM/0.3 mM), GalAG0 (0.5 mM/0.0516 mM), GalAG1 (0.25 mM/0.0486 mM), GalAG2 (0.03 mM/
0.018 mM), GalAxG2 (0.03 mM/0.016 mM), GalAxG3 (0.015 mM/0.017 mM), GalAxG3PS (0.015 mM/0.0146 mM), GalAxG4PS (0.01 mM/0.019 mM),
GalBG0 (1.0 mM/0.091 mM), GalBG1 (0.25 mM/0.049 mM), GalBG2 (0.03 mM/0.018 mM), GalBxG2 (0.03 mM/0.021 mM), GalBxG3 (0.015 mM/
0.013 mM). N = stoichiometry value in the ligand/galactose binding site on LecA. r.p./nGal = relative potency per galactosyl group relative to the
parent monovalent ligand GalAG0 or GalBG0.
Paper Organic & Biomolecular Chemistry
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synthesis series GalAxG2/GalAxG3 (107/148), although both
compounds were less potent than the parent GalAG2 dendri-
mer. Further generation increase was detrimental to binding,
as evidenced by a relative potency decrease by 1.6-fold in the
sequence GalAxPSG3/GalAxPSG4 (88/54). In the GalB series the
relative potency increase in the G0/G1/G2 series (1/18/230) was
comparable to that observed with the GalA series, in particular
with a 13-fold increase in relative potency when moving from
the divalent G1 dendrimer to the tetravalent G2 dendrimer,
which was comparable to the 16-fold increase observed in the
GalA series. As for the GalA series the gain in relative potency
was much smaller between the tetravalent G2 and octavalent G3
GalB type dendrimers and amounted to only 2.8-fold (280/785).
Taken together, the ITC data confirmed the hemagglutina-
tion inhibition assays in showing that, while a very strong
multivalency eﬀect occurred at the level of the tetravalent G2
dendrimers, only a relatively modest increase in relative
potency per galactosyl endgroup (1.4 to 4-fold) was possible by
moving to higher multivalency dendrimers. It should be noted
that ITC might not be able to measure KD values below 1 nM
and might therefore obscure an increase in potency in the rela-
tively tight binding GalA series. Nevertheless this uncertainly
should not aﬀect the results in the weaker binding GalB series
reaching KD = 5.9 nM for GalBxG3 reflecting a 2.8-fold increase
in relative potency per galactosyl group compared to its G2
analog.
Biofilm inhibition
P. aeruginosa biofilms were induced by growing the bacteria in
0.25% (w/v) nutrient broth no. 2, Oxoid, medium in 96-well
sterile, U-bottomed polystyrene microtiter plates. Biofilm inhi-
bition was determined by quantifying the amount of biofilm
formed after 24 h of growth in the presence or absence of
glycodendrimers or control compounds at diﬀerent concen-
trations. The biofilm was quantified using the WST-8 assay
indicating the amount of viable cells,19 rather than with the
crystal violet assay indicating the overall biomass.19b,19c,20
The results are reported as minimal biofilm inhibition con-
centration (MBIC), which is the lowest concentration inducing
complete biofilm inhibition (Table 3). In addition to biofilm
inhibition, the ability of the compound to disperse already
established biofilms was tested at a fixed concentration of
50 µM by treating established biofilms with the compounds
for 24 h, followed by quantification of the live attached cells as
above. The monovalent glycosides D-galactose, isopropyl thio-
galactoside (IPTG), GalAG0 and GalBG0 and dendrimers FD2,
GalAG2 and GalBG2 were used as controls since their biofilm
inhibition has been previously quantified using the steel
coupon assay.5b,12b,13 In particular D-galactose was inactive and
the monovalent glycosides were only very weakly active and
showed partial biofilm inhibition or dispersal only at milli-
molar to molar concentrations, while FD2, GalAG2 and
GalBG2 showed MBIC values of 20 µM (80 µM on a per carbo-
hydrate basis).
G2 dendrimers GalAxG2 and GalBxG2 obtained by the con-
vergent ClAc ligation approach had 2–3 fold higher MBIC
values than their parent dendrimers GalAG2 and GalBG2,
showing a slightly detrimental eﬀect of the modified peptide
backbone on the antibiofilm activity. Nevertheless the corres-
ponding G3 dendrimers GalAxG3 and GalBxG3 showed good
biofilm inhibition properties with MBIC ∼10 µM, which is
comparable to the inhibition by GalAG2 and GalBG2 on a per
galactose basis. These dendrimers were also very active in the
biofilm dispersal assay. Dendrimer GalAxPSG4, which was the
only G4 dendrimer obtained in suﬃcient yields to perform
biofilm inhibition studies, did not show any antibiofilm
activity, however the same was true for all dendrimers with a
Pro-Ser independent of their size, indicating a sequence rather
than a dendrimer generation eﬀect.
These data showed that the positive dendritic eﬀect on
biofilm inhibition in the series G0 (monovalent, no activity),
G1 (divalent, weak activity for GalA only), and G2 (tetravalent,
strong activity in both GalA and GalB) did not extend to higher
generations. Indeed the expansion to an octavalent, G3 dendri-
mer, although still beneficial for binding as observed in the
hemagglutination and ITC experiments, did not induce a sig-
nificant increase in biofilm inhibition, and expansion to G4
resulted in a loss of activity. These data clearly marked tetra-
valency of G2 dendrimers as the optimal multivalency in this
system. Although this pattern paralleled that of the relative
binding potency to LecA in these series, the lack of biofilm
inhibition activity with dendrimers built around a Pro-Ser core
despite their strong LecA binding showed that strong, multi-
valent LecA binding was necessary but not suﬃcient for
biofilm inhibition.
X-ray crystallography and molecular modeling
The fact that the relative binding potency and biofilm inhi-
bition per galactosyl group do not increase strongly beyond G2
dendrimers might reflect a steric crowding eﬀect preventing
Table 3 Bioﬁlm inhibition data
Compound ngal
a MBICa MBIC × nGal
b Biofilm dispersalc
D-Galactose 1 >450 mM — Inactive (100 mM)
IPTG 1 >360 mM — 25% (100 mM)
FD2 4 20 μM 80 μM 100%
GalAG0 1 >3 mM — 25% (0.5 mM)
GalAG1 2 225 µM 450 µM n.d.
GalAG2 4 20 µM 80 µM 50%
GalAxG2 4 40 µM 160 µM Inactive
GalAxG3 8 9 µM 72 µM 100%
GalAxG4 16 n.d. n.d. n.d.
GalAPSG2 4 >45 µM >180 µM n.d.
GalAxPSG3 8 >45 µM >360 µM n.d.
GalAxPSG4 16 >45 µM >720 µM 45%
GalBG0 1 >1.35 mM >2.6 mM Inactive (0.25 mM)
GalBG1 2 n.d. n.d. n.d.
GalBG2 4 20 µM 80 µM 60%
GalBxG2 4 60 µM 240 µM Inactive
GalBxG3 8 13 µM 104 µM 100%
aMBIC: minimal biofilm inhibition concentration. bMBIC corrected
for the number of galactosyl groups. c Biofilm dispersal with 50 μM
ligand.
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optimal interactions with LecA at the level of G3 and G4 den-
drimers. However the percentage of bound galactosyl groups
deduced from ITC data indicated that essentially all galactosyl
groups of G2 and G3 dendrimers were bound to LecA (>80%
bound galactose), while incomplete binding only occurred at
the level of GalAxPSG4 (40% bound galactose). A crystallo-
graphy and modeling study was therefore undertaken to
propose a binding mode for the octavalent G3 dendrimers
Fig. 2 Crystal structure and molecular modeling of G3 dendrimer LecA interactions. A. Side view and top view of the 3D checker-board lattice of
the GalAxPSG3. LecA complex in the crystal (PDB 5D21). One LecA tetramer (red) is shown surrounded by its eight neighbours making contact at
each of the eight corners. B. Details of the visible electron density of GalAxPSG3 and dendrimer–lectin binding interactions. C. Snapshot of the MD
simulation of a chelate bound GalAxG3·LecA complex. D. Snapshot of a chelate bound GalAxPSG3·LecA complex. E. Schematic representation of
LecA crystal lattice bound to a G3 dendrimer. F. Schematic representation of an extensive G3 dendrimer·LecA lattice accounting for saturation of all
galactosyl groups and galactose binding sites.
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capable of accounting for the complete saturation of all eight
galactosyl groups on the side of the G3 dendrimers and all
four galactose binding sites on the side of lectin LecA.
After screening several complexes and conditions, good
quality crystals of the complex GalAxPSG3·LecA were obtained
by soaking crystals of LecA with the dendrimer, providing a
structure at 1.9 Å resolution. In this structure LecA tetramers
are arranged in a 3D checker-board lattice leaving large cavities
available facing the galactose binding sites and which can be
occupied by a macromolecular ligand (Fig. 2A). All galactose
binding sites are indeed occupied by a phenyl-β-galactosyl
ligand, which under the conditions used for crystallization
must be part of the terminal arms of GalAxPSG3. The binding
interactions at the level of the phenyl-β-galactosyl groups com-
prise all the interactions observed previously in other aromatic
galactoside LecA complexes, including hydrogen-bonding
interactions between several hydroxyl groups on galactose and
residues H50, D100 and N107 on LecA, as well as the critical
CH–π interaction between the C(ε)–H of His50 of LecA and the
aromatic group of the phenyl galactoside (Fig. 2B).
No electron density is visible beyond the aromatic groups,
indicating a disordered conformation of the dendrimer or a
mixture of diﬀerent bound states. The surface of LecA sur-
rounding the galactose binding sites is almost entirely covered
by crystal water molecules, implying that GalAxG3PS binds
LecA exclusively via its phenyl-galactosyl groups and the visible
binding interactions. The positive dendritic eﬀect on binding
aﬃnity observed with GalAxG3PS and other G2 and G3 dendri-
mers in both hemagglutination and ITC (Table 3) can therefore
only be understood in terms of a chelate binding mode in
which two arms of the dendrimer bind to a pair of galactose
binding sites on the same side of the LecA tetramer. In the
context of the crystal structure the space available in the
checker-board lattice of the crystal is in any case large enough
to accommodate GalAxG3PS.
To test if chelate-bound structures might be possible we ran
independent molecular dynamics (MD) simulations of LecA
(as the tetramer) in complex with GalAxG3 and GalAxPSG3 in a
geometry compatible with the observed crystal structure. These
complexes remained stable over more than 5 ns of MD simu-
lations. In particular, the protein tetramer structure retained
the initial conformation seen in the X-ray model, with a global
Cα RMSD oscillating around 1.4 Å. Sampled structures show
how the dendrimer core can arrange into a rather compact
molten globule-like state, while single branches stretch out to
accommodate their ends into the binding pockets of the two
LecA subunits (Fig. 2C). The GalAxPSG3 dendrimer presents a
more compact structure than GalAxG3 due to the large
number of more rigid proline residues (Fig. 2D).
The above modeling studies suggest that G3 dendrimers
bind LecA in a chelate bound mode with a pair of galactosyl
groups combining with a pair of galactose binding sites on the
same side of LecA. G3 dendrimers are clearly too small to
bridge between the two pairs of galactose binding sites on
opposite sides of the same tetramer. The crystal structure of
the GalAxPSG3·LecA complex most likely corresponds to a 2 : 1
dendrimer/LecA tetramer stoichiometry engaging only a single
pair of galactosyl groups per dendrimer (Fig. 2E). ITC data by
contrast show that all galactoside groups engage in a binding
interaction with LecA, which can only occur with the opposite
1 : 2 dendrimer/LecA stoichiometry. Such stoichiometry might
occur in a cross-linked network accounting for the formation
of precipitates during ITC with all higher generation dendri-
mers (Fig. 2F).
Conclusion
In summary, convergent synthesis using the ClAc ligation as
the key step enabled an eﬃcient synthesis of G3 and
G4 glycopeptide dendrimer ligands for the galactose specific
P. aeruginosa lectin LecA bearing either 4-carboxyphenyl-
β-galactoside (GalA) or carboxypropyl-β-thiogalactoside (GalB)
end groups. LecA complexation studies by the hemagglutina-
tion assay and by ITC showed that the strong positive eﬀect on
the relative binding aﬃnity per galactosyl group observed up
to the tetravalent G2 dendrimers only partially extended to the
octavalent G3 dendrimers, and that G4 dendrimers had
decreased relative binding aﬃnities. Similar eﬀects were
observed in P. aeruginosa biofilm inhibition and dispersal
assays, with dendrimers GalAxG3 and GalBxG3 showing com-
parable activities to G2 dendrimers in biofilm inhibition and
slightly better activities in biofilm dispersal. A crystal structure
and modeling study was used to propose a lattice binding
model accounting for the saturation of all dendrimer galacto-
syl groups and LecA galactose binding sites for these potent
G3 dendrimers. Further studies with additional glycopeptide
dendrimers diversified using the eﬃcient ClAc ligation
approach are underway to decipher the structure–activity
relationships in this system in more detail and will be reported
in due course.
Materials and methods
Synthesis
Amino acids were used as the following derivatives: Fmoc-His
(Trt)-OH, Fmoc-Leu-OH, Fmoc-Phe-OH, Fmoc-Ile-OH, Fmoc-
Pro-OH, Fmoc-Lys(Boc)-OH, Fmoc-Lys(Fmoc)-OH, Fmoc-Cys
(Trt)-OH, Fmoc-Ser(tBu)-OH. Chemicals were used as supplied
and solvents were of analytical grade. Analytical RP-UHPLC
was performed in the Dionex ULTIMATE 3000 RS chromato-
graphy system (ULTIMATE 3000 RS photo diode array detector)
using a Dionex Acclaim® RSLC 120 C18, 3.0 × 50 mm, particle
size 2.2 μm, 120 Å pore size, flow rate 1.2 ml min−1 column.
Eluent A contained water with 0.1% TFA; eluent D contained
acetonitrile and water (90 : 10) with 0.1% TFA. Compounds
were detected by UV absorption at 214 nm. Preparative
RP-HPLC was performed with HPLC-grade acetonitrile and
MilliQ deionized water using a Dr Maisch GmbH Reprospher
C18-DE, 100 × 30 mm, particle size 5 μm, 100 Å pore size
column installed on a Waters Prep LC Controller system (flow
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rate 40 ml min−1). Eluent A contained water with 0.1% TFA;
eluent B contained acetonitrile and water (60 : 40) with 0.1%
TFA. MS spectra were provided by the Service of Mass Spectro-
metry of the Department of Chemistry and Biochemistry, Uni-
versity of Bern.
Solid phase peptide synthesis
Dendrimers were synthesized in the solid phase using Fmoc
chemistry in plastic syringes (10 mL) mounted on the axis of a
rotatory agitator for gentle stirring during reactions.21 Rink
amide NovaSyn® TGR resin (loading: 0.23 mmol g−1) (pur-
chased from Novabiochem) was acylated with each Fmoc-pro-
tected α-amino acid (3 eq.) in the presence of benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP)
(3 eq.) and N,N-diisopropylethylamine (DIEA) (5 eq.) in
N-methyl-2-pyrrolidone (NMP). The Fmoc-protecting groups
were removed with a solution of 20% piperidine in DMF.
When necessary the resin was chloroacetylated twice with a
solution of chloroacetic acid anhydride (10 eq.) in NMP for
20 min. At the end of the other sequences the terminal amino
acids were coupled with a protected sugar derivative (5 eq.) in
the presence of DIEA (5 eq.) and 2-(6-chloro-1H-benzotriazole-
1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate)
(HCTU) (3 eq.). The carbohydrate was deprotected with a solu-
tion of MeOH/NH3/H2O (v/v 8 : 1 : 1). The resin was dried and
the cleavage was carried out with TFA/triisopropylsilane/H2O
(95 : 2.5 : 2.5). Peptide dendrimers containing Cys residues
were cleaved with TFA/triisopropylsilane/H2O/1,2-ethanedithiol
(94 : 1 : 2.5 : 2.5). Peptide dendrimers were precipitated with
methyl tert-butyl ether and purified by preparative HPLC. The
compounds GalAG0, GalAG1, GalAG2, GalBG0, GalBG1 and
GalBG2 were prepared as previously described.13
Thioether ligation
A solution of the core dendrimer (sequence containing chloro-
acetyl endgroups, around 3 mg, 1 eq.) and KI (20 eq.) in DMF/
H2O (1 : 1, v/v) (300 µl) was prepared in a 2 mL glass vial. The
mixture was degassed with Ar for 10 min. In another 2 mL
glass vial arm dendrimer (Cys containing sequence, 1.5 eq. per
chloroacetyl endgroup in the core sequence) was weighed and
degassed with Ar for 10 min. The core dendrimer/KI solution
was transferred to the glass vial containing the arm dendrimer
via a gas-tight syringe. DIEA (55 eq.) was added and the solu-
tion was stirred overnight at room temperature under an Ar
atmosphere. The reaction was followed by analytical
RP-UHPLC. After 16 to 23 h, the reaction was quenched by the
addition of 3.5 mL of eluent A. After filtration, the solution
was directly purified by preparative RP-HPLC.
GalAG1-Cys (GalA-KP)2KIC was obtained from 500 mg resin
(loading 0.22 mmol g−1) as a foamy white solid after prepara-
tive RP-HPLC (63 mg, 45.76 μmol, 42%). Analytical RP-UHPLC:
tR = 1.257 min (A/D 100/0 to 0/100 in 2.2 min, λ = 214 nm). MS
(ESI+) calc. for C63H97N11O21S [M + H]
+: 1376.6, found 1376.6,
[M + H]+/2688.6
GalBG1-Cys (GalB-KP)2KIC was obtained from 500 mg resin
(loading 0.22 mmol g−1) as a foamy white solid after prepara-
tive RP-HPLC (57 mg, 43.43 μmol, 40%). Analytical RP-UHPLC:
tR = 1.217 min (A/D 100/0 to 0/100 in 2.2 min, λ = 214 nm). MS
(ESI+) calc. for C55H97N11O19S3 [M + H]
+: 1312.6, found 1312,
[M + H]+/2656.8
ClAcG1 (ClAc-KI)2KHI was obtained from 500 mg resin
(loading 0.22 mmol g−1) as a foamy white solid after prepara-
tive RP-HPLC (41.4 mg, 40.18 μmol, 33%). Analytical
RP-UHPLC: tR = 0.990 min (A/D 80/20 to 0/100 in 2.2 min, λ =
214 nm). MS (ESI+) calc. for C46H81Cl2N13O9 [M + H]
+: 1031.1,
found 1030.4, [M + H]+/2515.8; [M + H]+/3344.6
ClAcG2 (ClAc-KP)4(KKI)2KHI was obtained from 500 mg
resin (loading 0.22 mmol g−1) as a foamy white solid after pre-
parative RP-HPLC (64 mg, 27.34 μmol, 25%). Analytical
RP-UHPLC: tR = 1.345 min (A/D 100/0 to 0/100 in 2.2 min, λ =
214 nm). MS (ESI+) calc. for C106H183Cl4N29O21 [M + H]
+:
2341.6, found 2341.0.
ClAcG3 (ClAc-KP)8(KLF)4(KKI)2KHI was obtained from
500 mg resin (loading 0.25 mmol g−1) as a foamy white solid
after preparative RP-HPLC (19.3 mg, 3.78 μmol, 3%). Analytical
RP-UHPLC: tR = 1.647 min (A/D 100/0 to 0/100 in 2.2 min, λ =
214 nm). MS (ESI+) calc. for C242H391Cl8N57O45 [M + H]
+:
5102.7, found 5102.
ClAcPSG2 (ClAc-PS)4(KPS)2KPS was obtained from 500 mg
resin (loading 0.22 mmol g−1) as a foamy white solid after pre-
parative RP-HPLC (66 mg, 33.07 μmol, 30%). Analytical
RP-UHPLC: tR = 1.285 min (A/D 90/10 to 0/100 in 2.2 min, λ =
214 nm). MS (ESI+) calc. for C82H127Cl4N21O28 [M + H]
+:
1996.8, found 1995.9, 2033.9 [M + K]+, 2056.4 [M + K + Na]+.
ClAcPSG3 (ClAc-PS)8(KPS)4(KPS)2KPS was obtained from
500 mg resin (loading 0.22 mmol g−1) as a foamy white solid
after preparative RP-HPLC (25 mg, 5.83 μmol, 5%). Analytical
RP-UHPLC: tR = 1.38 min (A/D 90/10 to 0/100 in 2.2 min, λ =
214 nm). MS (ESI+) calc. for C178H275Cl8N45O60 [M + H]
+: 4289,
found 4290 and several sodium and potassium adducts.
GalAPSG2 (GalA-KPL)4(KPS)2KPS was obtained from 500 mg
resin (loading 0.25 mmol g−1) as a foamy white solid after pre-
parative RP-HPLC (26.4 mg, 7.68 μmol, 6%). Analytical
RP-UHPLC: tR = 2.635 min (A/D 100/0 to 0/100 in 7.5 min, λ =
214 nm). MS (ESI+) calc. for C162H251N29O52 [M + H]
+: 3437.89,
found 3437.8. Calc. for [M + K]+: 3475.89, found 3975.7.
GalAxG2 (GalA-KP)4(KICxKI)2KHI was obtained as a foamy
white solid after preparative RP-HPLC (6.9 mg, 1.86 μmol,
68%). Analytical RP-UHPLC: tR = 1.944 min (A/D 100/0 to 0/100
in 4.5 min, λ = 214 nm). MS (ESI+) calc. for C172H273N35O51S2
[M + H]+: 3711.3, found 3711.0.
GalAxG3 (GalA-KP)8(KICxKP)4(KKI)2KHI was obtained as a
foamy white solid after preparative RP-HPLC (6.6 mg,
0.86 μmol, 67%). Analytical RP-UHPLC: tR = 1.799 min (A/D
100/0 to 0/100 in 4.5 min, λ = 214 nm). MS (ESI+) calc. for
C358H567N73O105S4 [M + H]
+: 7702, found 7701.0; [M + H] +
adducts with trifluoroacetic acid (TFA).
GalAxG4 (GalA-KP)16(KICxKP)8(KLF)4(KKI)2KHI was
obtained as a foamy white solid after preparative RP-HPLC
(1.1 mg, 0.07 μmol, 12%). Analytical RP-UHPLC: tR = 2.094 min
(A/D 100/0 to 0/100 in 4.5 min, λ = 214 nm). MS (ESI+) calc. for
C746H1159N145O213S8 [M + H]
+: 15 824, found 15 825.
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GalAxPSG3 (GalA-KP)8(KICxPS)4(KPS)2KPS was obtained as
a foamy white solid after preparative RP-HPLC (8.2 mg,
1.11 μmol, 74%). Analytical RP-UHPLC: tR = 2.519 min (A/D
100/0 to 0/100 in 7.5 min, λ = 214 nm). MS (ESI+) calc. for
C334H511N65O112S4 [M + H]
+: 7357.3, found 7358.0, [M + K]+
7395.0
GalAxPSG4 (GalA-KP)16(KICxPS)8(KPS)4(KPS)2KPS was
obtained as a foamy white solid after preparative RP-HPLC
(9.1 mg, 0.61 μmol, 81%). Analytical RP-UHPLC: tR = 1.878 min
(A/D 100/0 to 0/100 in 4.5 min, λ = 214 nm). MS (ESI+) calc. for
C682H1043N133O228S8 [M + H]
+: 15 010, found 15 010.3.
GalBxG2 (GalB-KP)4(KICxKI)2KHI was obtained as a foamy
white solid after preparative RP-HPLC (5.2 mg, 1.45 μmol,
50%). Analytical RP-UHPLC: tR = 1.839 min (A/D 100/0 to 0/100
in 4.5 min, λ = 214 nm). HRMS (ESI+) calc. for
C156H273N35O47S6 [M + H]
+: 3583.4, found 3582.84.
GalBxG3 (GalB-KP)8(KICxKP)4(KKI)2KHI was obtained as a
foamy white solid after preparative RP-HPLC (4.9 mg,
0.66 μmol, 51%). Analytical RP-UHPLC: tR = 1.784 min (A/D
100/0 to 0/100 in 4.5 min, λ = 214 nm). MS (ESI+) calc. for
C326H567N73O97S12 [M + H]
+: 7446, found 7445.0.
Hemagglutination assays
Erythrocyte preparation. Rabbit red cells (erythrocytes 50%;
Biomerieux) separated from the preservative by centrifugation
(1500 RPM; 10 min) were washed three times with 0.9% NaCl
solution (saline) and suspended to a concentration of 5% v/v
in phosphate buﬀer saline (PBS; 0.01 M; pH 7.4). The suspen-
sion was given papain-treatment which includes incubation of
9 volumes of the 5% cell suspension with 1 volume of 1% w/v
papain (crude preparation, Sigma) in 0.1% w/v L-cysteine solu-
tion at 37 °C for 30 min. The enzyme treated cells were washed
three times in PBS and then resuspended in it to a concen-
tration of 5%.
LecA titration. In order to determine the lectin concen-
tration needed to agglutinate the cells, decreasing amounts of
LecA were incubated with red blood cells. Serial two fold
dilutions were made in the wells of a microtiter plate (96-well
microtiter non-treated V-bottom plates, Nunc, Denmark). Two
fold dilutions were made by adding 50 µL of buﬀer solution to
all the 24 wells and 50 µL of LecA solution (0.34 mg ml−1) to
the first well. 50 µL was then transferred from the first well to
the second. The second well was mixed and 50 µL was trans-
ferred to the third well. This procedure was repeated until the
24th well. To each well 50 µL of the RBC solution (5% in PBS)
was added and incubated for 30 min at 4 °C. After this time,
plates were centrifuged for 30 s (1000g), the wells were exam-
ined and the minimum amount of LecA required to aggluti-
nate the cell suspension was determined. This was then
considered to be 1 HA unit. For the inhibition assay an 8 HA
unit LecA solution was made up.
Minimum inhibitory concentration (MIC) determination. A
50 µL sample of each inhibitor examined was serially diluted
with 50 µL PBS in the microtiter plate to produce twofold
dilutions (as described above). The inhibitor solutions were
incubated with 50 µL of the 8 HA unit LecA solution (Conc. of
LecA = 5.31 µg mL−1) for 30 min at 4 °C. After this time 50 µL
of the erythrocytes in PBS suspensions (Conc. 5%) was added
and the wells were mixed and incubated for one hour at room
temperature. The plates were then centrifuged for 30 s (1000g).
Each test was performed in triplicate. The activity of the tested
compounds was recorded as minimal inhibitory concentration
(MIC), corresponding to the highest dilution causing a com-
plete inhibition of hemagglutination (ESI Fig. S46†).
Isothermal titration calorimetry (ITC)
Lyophilized LecA was dissolved in buﬀer (Tris 20 mM, NaCl
100 mM, CaCl2 100 µM, pH = 7.5). Protein concentration was
checked by the measurement of absorbance at 280 nm using
1 Abs = 2.116 mg ml−1 (Mw = 12 893 g mol
−1) using a Nano-
Drop instrument. The ligands were dissolved directly into the
same buﬀer. ITC was performed with an iTC200 calorimeter
(MicroCal Inc.). Titration was performed on 0.0146–0.3 mM
LecA in the 200 µl sample cell using 2 µl injections of
0.01–01 mM ligand every 120 s at 25 °C. The data were fitted
with MicroCal Origin 8 software, according to standard pro-
cedures using a single-site model. The change in free energy
ΔG was calculated from the equation: ΔG = ΔH − TΔS where
T is the absolute temperature, ΔH and ΔS are the change in
enthalpy and entropy respectively. Two independent titrations
were performed for each ligand tested.
Biofilm inhibition
A modified version of the method described by Diggle et al.
was employed.5b 96-well sterile, U-bottomed polystyrene micro-
titre plates (TPP Switzerland) were prepared by adding 200 μl
of sterile deionized water to the peripheral wells to decrease
evaporation from test wells. Aliquots of 180 μl of culture
medium (10% (w/v) nutrient broth no. 2, Oxoid) containing
desired concentrations of the test compound were added to
the internal wells. The inoculum of P. aeruginosa strain PAO1
was prepared from 5 ml of an overnight culture grown in LB
broth. Aliquots of 20 μl of overnight cultures, pre-washed in
10% (w/v) nutrient broth and normalized to an OD600 of 1,
were inoculated into the test wells. The plates were incubated
in a humid environment for 25 hours at 37 °C. The wells were
washed with 200 μl sterile deionized water before staining with
200 μl 10% (w/v) nutrient broth containing 0.5 mM WST-8 and
20 μM phenazine ethosulfate for 3 hours at 37 °C. Afterwards,
the supernatants from the well were transferred to a poly-
styrene flat bottomed 96-well plate (TPP Switzerland) and the
absorbance was measured at 450 nm with a plate reader
(SpectraMax250 from Molecular Devices).
Crystallization of GalAxPSG3·LecA
LecA was expressed and purified by aﬃnity chromatography
along an optimized protocol and in accordance with a previous
report.17 The crystals of the GalAxPSG3·LecA complex were
obtained by soaking. For this, LecA crystals were grown under
a condition containing 1.5 M ammonium sulfate at a pH of 4.6
which is the SaltRx II 13 condition. The crystals grew within
3–4 days. Drops of 4 μL containing the crystals were sup-
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plemented with GalAPSG3 at 15 binding equivalents of the
compound, respectively. The soaked crystals were incubated at
18 °C for 3–4 days, transferred into a solution of 1.5 M
ammonium sulfate supplemented with 30% v/v glycerol at pH
4.6 and immediately flash frozen in liquid nitrogen for
storage. Further details on data collection statistics are given
in Table S1†. Crystals were cryocooled at 100 K after soaking
them for as short a time as possible in glycerol 30% v/v in a
precipitant solution. All data were collected at the SLS synchro-
tron (Villigen, Switzerland) at beamline PX-II/III. The struc-
tures were solved with CCP4 and Phenix.22,23
Molecular modeling
The crystal structure of GalAxPSG3·LecA obtained above was
used to model the dendrimer·LecA complexes. Two systems
were considered: (i) LecA in complex with GalAxG3 and (ii)
LecA in complex with GalAxPSG3. The initial configurations
were built using Corina,24 imposing two binding units of GalA
in two binding pockets of the respective LecA subunits. The
missing hydrogen atoms were added to the protein structure
using the default protonation states at pH = 7. The amber
force field (FF99SB)25 was used to describe intra- and inter-
molecular interactions. The electrostatic point-charges for the
GalA unit, and for the branching lysine and modified cysteine
amino acids present in the dendrimer structures were
obtained using the standard RESP procedure.26 The GalAxPS-
G3·LecA and GalAxG3·LecA systems were solvated by 60 531
and 71 608 water molecules and placed in a truncated octa-
hedral water box. The TIP3P water model27 was used to add
the solvent. Particle mesh Ewald routines were used to treat
long-range electrostatic interactions.28 A cutoﬀ of 11 Å was
used for the van der Waals interactions and the real part of the
electrostatic potential. The simulations were performed using
Langevin dynamics for temperature regulation.29 Bonds com-
prising hydrogen atoms were constrained with the SHAKE con-
straint algorithm.30 All simulations were performed using the
AMBER12 31 program and the trajectories were analyzed using
VMD.32 First, energy minimization on the entire system was
carried out using the steepest descent algorithm for the first
1000 steps followed by 2500 steps of conjugate gradient algo-
rithm. The solvent was then heated up from 0 to 300 K in
200 ps MD, using a time step of 2 fs. This step assigns weak
positional restraints on the solute. After this procedure the
whole system was energy minimized. Finally production runs
of 5 ns were performed at 300 K.
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